X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Neurology Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
Details:
The cross-border distribution strategy allows for Tru Niagen® (nicotinamide riboside) 300mg 30 count bottles, Tru Niagen® 300mg 90 count bottles and Tru Niagen® 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MyPharma2Go Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 01, 2022
Details:
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Nutrition and Weight Loss Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ChromaDex, Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 10, 2022
Details:
Tru Niagen Immune, is a combination of ingredient Niagen (nicotinamide riboside), and Theracurmin (curcumin) is first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
A newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen (nicotinamide riboside) ingredient and other nicotinamide adenine dinucleotide (NAD) precursors.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Product Name: Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Details:
Results of phase I clinical trial for Niagen, showed that NR supplementation significantly increased cerebral nicotinamide adenine dinucleotide levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in patients with PD.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Neurology Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
Niagen® replenishes levels of NAD+, supports healthy cellular metabolism, and helps mitochondria function more eciently to promote healthy aging at the cellular level.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Ophthalmology Product Name: Niagen
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Details:
ChromaDex’s proprietary healthy aging ingredient Niagen®, the world’s first and only FDA-safety reviewed and patented form of nicotinamide riboside, will be added to multi-ingredient Designs for Health formulas.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Product Name: Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Designs for Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 20, 2022
Details:
The study investigated ChromaDex’s proprietary Niagen® ingredient (patented nicotinamide riboside, or “NR”) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder with premature aging, cerebellar degeneration and cancer predisposition.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Rare Diseases and Disorders Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2021
Details:
Tru Niagen® is a unique form of vitamin B3 that is clinically proven to elevate NAD+, reducing the impact of aging and daily wear and tear on the body.
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Dermatology Product Name: Tru Niagen
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
Details:
The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
Lead Product(s): Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
The prior study suggested that NR supplementation could facilitate cancer treatment by preventing myelosuppression in mice, (i.e. depletion of stem cells and all the cells they produce, caused by repeated chemotherapies).
Lead Product(s): Nicotinamide Riboside
Therapeutic Area: Oncology Product Name: Niagen
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The Phase 2 study reported patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time when receiving the standard of care in combination with a nutritional protocol including nicotinamide riboside (NR).
Lead Product(s): Nicotinamide Riboside,Hydroxychloroquine Sulphate,Serine
Therapeutic Area: Infections and Infectious Diseases Product Name: Niagen
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
